CoChat

Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?

Open access
Heine, R J, Diamant, M, Mbanya, J-C, Nathan, D M · 2006 · BMJ
Cited by 100

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

The epidemic of type 2 diabetes imposes an enormous and growing burden on health care worldwide. The number of people with type 2 diabetes around the world is estimated to rise from 151 million in 2000 to 300 million by 2025.1 The recognition that strict glycaemic control can reduce microvascular complications has made the effective treatment of hyperglycaemia a priority.2 3 4 5 6 Recently, the diabetes control and complications trial reported that intensive therapy aimed at normoglycaemia has beneficial effects on cardiovascular disease in type 1 diabetes.7 In type 2 diabetes, epidemiological data from the UK prospective diabetes study suggest that lowering glycaemia will reduce the risk of cardiovascular disease.8 The treatment of hyperglycaemia in type 2 diabetes is complex; combinations of glucose lowering drugs are often needed to achieve and maintain blood glucose at target values. The development of new classes of drugs to lower blood glucose has increased the treatment options for type 2 diabetes and has contributed to the uncertainty surrounding these new therapeutic approaches. Here we present a management guideline that may help healthcare providers treat patients with type 2 diabetes. #### Sources and selection criteria This review is largely based on the recently published American Diabetes Association/European Association for the Study of Diabetes treatment guideline for type 2 diabetes.9 We also searched the Cochrane Library for evidence based guidelines using the keywords “type 2 diabetes”, “blood glucose lowering agents”, “glucose monitoring”, “lifestyle”, and “exercise and diet” Studies have shown that the development of microvascular disease is reduced when glycaemic control is improved and have helped establish treatment targets for glycaemia in type 2 diabetes.4 6 Ideally glycated haemoglobin (HbA1C) should be as close to normal as possible without imposing a high risk of severe hypoglycaemia. The upper limit of normal of the …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.39022.462546.80

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 100

Metadata

Authors
Heine, R. J., Diamant, M., Mbanya, J.-C., & Nathan, D. M.
Venue
BMJ
Publisher
BMJ
Published
2006-12-07
Volume
333
Issue
7580
Pages
1200-1204
ISSN
  • 0007-1447 (ISSN-L)
  • 0959-8138
  • 1468-5833
OpenAlex
W2050297766
Cited by
100
References
17
FWCI
3.23
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure? https://app.cochat.ai/papers/10.1136/bmj.39022.462546.80
The paper
Heine, R. J., Diamant, M., Mbanya, J.-C., & Nathan, D. M. (2006). Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure? BMJ. https://doi.org/10.1136/bmj.39022.462546.80

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.